Adaptimmune TherapeuticsADAP
About: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
Employees: 506
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
167% more call options, than puts
Call options by funds: $24K | Put options by funds: $9K
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
1.85% less ownership
Funds ownership: 9.95% [Q3] → 8.1% (-1.85%) [Q4]
3% less funds holding
Funds holding: 80 [Q3] → 78 (-2) [Q4]
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
54% less capital invested
Capital invested by funds: $145M [Q3] → $67M (-$78.1M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Arthur He 14% 1-year accuracy 3 / 22 met price target | 884%upside $3 | Buy Maintained | 1 Apr 2025 |
Guggenheim Michael Schmidt 7% 1-year accuracy 1 / 14 met price target | 474%upside $1.75 | Buy Maintained | 26 Mar 2025 |
Wells Fargo Yanan Zhu 11% 1-year accuracy 1 / 9 met price target | 392%upside $1.50 | Equal-Weight Maintained | 21 Mar 2025 |
Scotiabank George Farmer 0% 1-year accuracy 0 / 1 met price target | 359%upside $1.40 | Sector Outperform Maintained | 21 Mar 2025 |
Financial journalist opinion
Based on 3 articles about ADAP published over the past 30 days









